Insmed, Inc. (INSM)
126.29
-0.39
(-0.31%)
USD |
NASDAQ |
Sep 04, 16:00
126.30
+0.01
(+0.01%)
Pre-Market: 20:00
Insmed Research and Development Expense (Quarterly) : 210.03M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 210.03M |
| March 31, 2026 | 209.48M |
| December 31, 2025 | 254.91M |
| September 30, 2025 | 186.42M |
| June 30, 2025 | 177.19M |
| March 31, 2025 | 152.58M |
| December 31, 2024 | 179.73M |
| September 30, 2024 | 150.81M |
| June 30, 2024 | 146.75M |
| March 31, 2024 | 121.08M |
| December 31, 2023 | 137.03M |
| September 30, 2023 | 109.15M |
| June 30, 2023 | 196.97M |
| March 31, 2023 | 127.86M |
| December 31, 2022 | 124.76M |
| September 30, 2022 | 99.87M |
| June 30, 2022 | 88.53M |
| March 31, 2022 | 84.36M |
| December 31, 2021 | 76.35M |
| September 30, 2021 | 70.35M |
| June 30, 2021 | 64.66M |
| March 31, 2021 | 61.39M |
| December 31, 2020 | 67.81M |
| September 30, 2020 | 41.41M |
| June 30, 2020 | 35.75M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.18M |
| December 31, 2019 | 32.63M |
| September 30, 2019 | 34.34M |
| June 30, 2019 | 33.54M |
| March 31, 2019 | 31.20M |
| December 31, 2018 | 39.92M |
| September 30, 2018 | 39.54M |
| June 30, 2018 | 35.72M |
| March 31, 2018 | 30.10M |
| December 31, 2017 | 33.95M |
| September 30, 2017 | 26.68M |
| June 30, 2017 | 26.87M |
| March 31, 2017 | 22.25M |
| December 31, 2016 | 54.87M |
| September 30, 2016 | 23.43M |
| June 30, 2016 | 23.87M |
| March 31, 2016 | 20.55M |
| December 31, 2015 | 19.65M |
| September 30, 2015 | 19.22M |
| June 30, 2015 | 18.25M |
| March 31, 2015 | 17.16M |
| December 31, 2014 | 14.80M |
| September 30, 2014 | 15.20M |
| June 30, 2014 | 14.94M |
| March 31, 2014 | 11.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Biogen, Inc. | 461.70M |
| Gilead Sciences, Inc. | 1.69B |
| Agios Pharmaceuticals, Inc. | 99.40M |
| Arcutis Biotherapeutics, Inc. | 20.36M |